Ekaterina Nevedomskaya

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index2.9kcitations186works9.72yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(61), RNA Research and Splicing(29), Prostate Cancer Treatment and Research(28), MicroRNA in disease regulation(22), Molecular Biology Techniques and Applications(22)

Publications184 total

Abstract 3157: Novel synthetic lethality-based cellular assays for cancer drug discovery
Cancer Research·2025
Dual targeting of the androgen receptor and <scp>PI3K</scp> / <scp>AKT</scp> / <scp>mTOR</scp> pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis
Molecular Oncology·2024· 20 citedOpen Access
Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review
International Journal of Molecular Sciences·2024· 9 citedOpen Access
Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?
European Urology Open Science·2023· 1 citedOpen Access
Author response for "Dual targeting of the androgen receptor and &lt;scp&gt;PI3K&lt;/scp&gt;/&lt;scp&gt;AKT&lt;/scp&gt;/&lt;scp&gt;mTOR&lt;/scp&gt; pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis"
2023
Author response for "Dual targeting of the androgen receptor and &lt;scp&gt;PI3K&lt;/scp&gt;/&lt;scp&gt;AKT&lt;/scp&gt;/&lt;scp&gt;mTOR&lt;/scp&gt; pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis"
2023
Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor–driven Programs
European Urology·2023· 10 citedOpen Access
Abstract B065: Combining the androgen receptor inhibitor darolutamide with PI3K/AKT/mTOR pathway inhibitors has superior efficacy in preclinical models of prostate cancer
Cancer Research·2023
Targeting fatty acid oxidation via Acyl-CoA binding protein hinders glioblastoma invasion
Cell Death and Disease·2023· 21 citedOpen Access
Supplemental doc from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma
2023Open Access
Table S1 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma
2023Open Access
Table S5 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma
2023Open Access
Table S6 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma
2023Open Access
Table S4 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma
2023Open Access
Table S3 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma
2023Open Access
Data from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma
2023Open Access
Table S5 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma
2023Open Access
Table S1 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma
2023Open Access
Table S4 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma
2023Open Access
Table S2 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Wilbert Zwart(20), Oleg A. Mayboroda(15), André M. Deelder(13), Lodewyk F.A. Wessels(12), Bernard Haendler(10), Suzan Stelloo(10), Andries M. Bergman(10), Simon J. Baumgart(7), Yongsoo Kim(6), Henk G. van der Poel(6), Marjolein Droog(6), Ralf Lesche(6), Dominik Mumberg(5), Rico J. E. Derks(5), Tiziana Pacchiarotta(5), Jason S. Carroll(4), Jeroen de Jong(4), Alegría Carrasco‐Pancorbo(4), Daniel S. Peeper(3), Oscar Krijgsman(3)